DM Intelligence Medicine Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin), LRRK2 (G2019S mutant) and/or EGFR (HER1; erbB1 mutant) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders.
Cstone Pharmaceuticals Co. Ltd. has filed a clinical trial application in Australia seeking to initiate a first-in-human study of CS-2009 for solid tumors. The company plans to initiate a multi-regional trial for CS-2009 in Australia early next year, followed by expansion into China and the U.S.
Differentiated thyroid cancers (DTC) and anaplastic thyroid cancers (ATC) often develop primary and acquired resistance to standard treatments. This highlights the need for new therapeutic strategies to treat these thyroid tumors. Previous research observed that the pyrimidine ring of the 2,4-diaminopyrimidine moiety could often form critical hydrogen bonds with kinases, leading to strong inhibitory activity.
Researchers from Nanjing University and Peking University presented the discovery and preclinical characterization of novel NLRP3 inhibitors as potential therapeutic candidates for the treatment of gout.
Radiopharm Theranostics Ltd. has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I therapeutic study of 177Lu-labeled RAD-202 (177Lu-RAD-202) for the treatment of HER2-expressing solid tumors, including breast and gastric cancers.
Basilea Pharmaceutica Ltd. has been awarded an additional $7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the progression of the company’s novel antibiotic candidate, BAL-2420.
Beigene Co. Ltd. has presented data on a CDK4 selective inhibitor, BGB-43395, for the potential treatment of this cancer type and which would reduce the neutropenia associated with CDK6 inhibition.
Vanda Pharmaceuticals Inc.’s VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor, has been awarded orphan drug designation by the FDA for the treatment of polycythemia vera.
CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials of antibody-drug conjugates (ADCs) SYS-6005 and SYS-6043.
RSS
